MOLECULAR GENETICS OF NUCLEOLAR DOMINANCE

核仁优势的分子遗传学

基本信息

  • 批准号:
    8109976
  • 负责人:
  • 金额:
    $ 30.17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-04-01 至 2013-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Nucleolar dominance is an epigenetic phenomenon that occurs in plant and animal genetic hybrids and describes the transcription of ribosomal RNA (rRNA) genes inherited from only one parent due to the selective silencing of the other progenitor's rRNA genes. The silencing that occurs in nucleolar dominance happens on a scale of millions of basepairs, second in scope only to X chromosome inactivation in female mammals. Unique aspects of nucleolar dominance are that the choice of rRNA genes to silence is not random nor is it dictated by maternal or paternal imprints. The mechanisms responsible for selectively inactivating one parental set of rRNA genes in nucleolar dominance are not clear. Likewise, it is not clear how silencing decisions are made for hundreds of other genes that display monoallelic expression, for genes that are subjected to developmentally controlled silencing, or for tumor suppressor genes that become silenced in numerous forms of cancer. Therefore, understanding the molecular mechanisms responsible for nucleolar dominance has broad relevance in genetics, developmental biology and medicine. In Arabidopsis suecica, the allotetraploid hybrid of A. thaliana and A. arenosa, the A. thaliana- derived rRNA genes are silenced. Under the current grant, we identified multiple activities required for rRNA gene silencing, including a de novo DNA methyltransferase, methylcytosine binding domain proteins, histone deacetylases and histone methyltransferases. Importantly, we recently found that rRNA gene silencing is RNA and Dicer-dependent, involving components of the siRNA-directed DNA methylation pathway. Because homologous pairing of siRNAs with complementary sequences has the potential to discriminate between parental sets of rRNA genes, this discovery has the potential to reveal the choice mechanism(s) in nucleolar dominance. Moreover, siRNAs implicated in rRNA gene silencing derive from intergenic non-coding RNA (ncRNA) precursors, which are the most prevalent class of transcripts generated in the nucleus, yet the least understood. At present, we do not know whether siRNAs, their precursor transcripts, or chromatin modifications resulting from the act of intergenic spacer transcription are what mediate rRNA gene silencing, and testing these alternative hypotheses is a priority. Using a combination of genetic, cytological, bioinformatic and biochemical approaches, our short-term goals are to understand the interplay between the non-coding intergenic RNAs and the chromatin modifying activities that are involved in rRNA gene silencing. These efforts will contribute to our long-term goals of understanding the mechanisms responsible for nucleolar dominance and the mechanisms capable of silencing chromosomal loci on a megabase scale. PUBLIC HEALTH RELEVANCE: Gene silencing plays an important role in controlling the sets of genes that are repressed in specific cell types during development, in controlling the dosage of X-linked genes in mammals and in determining the parent-specific expression of imprinted genes in animals and plants. Gene silencing also plays an important role in genome defense by suppressing the activity of transposons and retroviruses. However, gene silencing has a dark side, including the silencing of tumor suppressor genes in many forms of cancer. An ability to specifically derepress tumor suppressor genes would be desirable as a cancer treatment. Likewise, the ability to derepress specific members of multigene families would be desirable as a treatment for certain genetic disorders. For instance, thalassemias that result from mutations in adult-specific globin genes might be alleviated by derepression of functional globin genes that were expressed during fetal development but were then developmentally silenced. Understanding the mechanisms responsible for gene silencing therefore has relevance to basic science as well as medicine. The unique aspects of rRNA gene silencing in nucleolar dominance will contribute to this understanding.
描述(由申请人提供):核仁显性是一种表观遗传现象,发生在植物和动物遗传杂种中,描述了由于选择性沉默另一个祖先的rRNA基因而导致仅从一个亲本遗传的核糖体RNA(rRNA)基因的转录。核仁优势中的沉默发生在数百万个碱基对的范围内,仅次于雌性哺乳动物中的X染色体失活。核仁优势的独特之处在于沉默rRNA基因的选择不是随机的,也不是由母亲或父亲的印记决定的。在核仁优势中选择性失活一组亲本rRNA基因的机制尚不清楚。同样,目前还不清楚如何沉默决定数百个其他基因显示单等位基因表达,基因受到发育控制沉默,或成为沉默的肿瘤抑制基因在许多形式的癌症。因此,了解核仁优势的分子机制在遗传学、发育生物学和医学中具有广泛的意义。在拟南芥(Arabidopsis suecica)中,A.和拟南芥A. arenosa,A.拟南芥衍生的rRNA基因被沉默。在目前的资助下,我们确定了rRNA基因沉默所需的多种活动,包括从头DNA甲基转移酶,甲基胞嘧啶结合结构域蛋白,组蛋白脱乙酰酶和组蛋白甲基转移酶。重要的是,我们最近发现rRNA基因沉默是RNA和Dicer依赖性的,涉及siRNA指导的DNA甲基化途径的组分。由于siRNA与互补序列的同源配对具有区分亲本rRNA基因组的潜力,因此这一发现具有揭示核仁优势中的选择机制的潜力。此外,参与rRNA基因沉默的siRNA来源于基因间非编码RNA(ncRNA)前体,其是在细胞核中产生的最普遍的一类转录物,但了解最少。目前,我们不知道siRNA、其前体转录物或由基因间间隔区转录行为引起的染色质修饰是否介导rRNA基因沉默,并且测试这些替代假设是优先考虑的。使用遗传学,细胞学,生物信息学和生物化学方法的组合,我们的短期目标是了解非编码基因间RNA和染色质修饰活动,参与rRNA基因沉默之间的相互作用。这些努力将有助于我们的长期目标,了解负责核仁优势的机制和机制,能够沉默染色体位点的兆规模。 公共卫生关系:基因沉默在控制发育过程中在特定细胞类型中被抑制的基因组、控制哺乳动物中X连锁基因的剂量以及决定动植物中印记基因的亲本特异性表达方面起着重要作用。基因沉默还通过抑制转座子和逆转录病毒的活性在基因组防御中起重要作用。然而,基因沉默也有黑暗的一面,包括许多形式的癌症中的肿瘤抑制基因的沉默。特异性地去抑制肿瘤抑制基因的能力作为癌症治疗将是期望的。同样,作为某些遗传疾病的治疗,去抑制多基因家族的特定成员的能力将是期望的。例如,由成人特异性珠蛋白基因突变引起的地中海贫血可能会通过功能性珠蛋白基因的去抑制来缓解,这些基因在胎儿发育期间表达,但随后在发育中沉默。因此,了解基因沉默的机制对基础科学和医学都有意义。rRNA基因沉默在核仁优势中的独特方面将有助于这种理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CRAIG Stuart PIKAARD其他文献

CRAIG Stuart PIKAARD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CRAIG Stuart PIKAARD', 18)}}的其他基金

SPECIFICITY OF HISTONE ACETYLTRANSFERASE ENZYMES FROM ARABIDOPSIS THALIANA
拟南芥组蛋白乙酰转移酶的特异性
  • 批准号:
    7953917
  • 财政年份:
    2009
  • 资助金额:
    $ 30.17万
  • 项目类别:
SPECIFICITY OF HISTONE ACETYLTRANSFERASE ENZYMES FROM ARABIDOPSIS THALIANA
拟南芥组蛋白乙酰转移酶的特异性
  • 批准号:
    7721482
  • 财政年份:
    2008
  • 资助金额:
    $ 30.17万
  • 项目类别:
Roles of RNA Polymerases IV and V in siRNA-mediated gene silencing
RNA 聚合酶 IV 和 V 在 siRNA 介导的基因沉默中的作用
  • 批准号:
    8391724
  • 财政年份:
    2006
  • 资助金额:
    $ 30.17万
  • 项目类别:
Role of RNA polymerase IV in the heterochromatic siRNA pathway
RNA聚合酶IV在异染色质siRNA途径中的作用
  • 批准号:
    7599659
  • 财政年份:
    2006
  • 资助金额:
    $ 30.17万
  • 项目类别:
Roles of RNA Polymerases IV and V in siRNA-mediated gene silencing
RNA 聚合酶 IV 和 V 在 siRNA 介导的基因沉默中的作用
  • 批准号:
    8204558
  • 财政年份:
    2006
  • 资助金额:
    $ 30.17万
  • 项目类别:
Role of RNA polymerase IV in the heterochromatic siRNA pathway
RNA聚合酶IV在异染色质siRNA途径中的作用
  • 批准号:
    8037901
  • 财政年份:
    2006
  • 资助金额:
    $ 30.17万
  • 项目类别:
SPECIFICITY OF HISTONE ACETYLTRANSFERASE ENZYMES FROM ARABIDOPSIS THALIANA
拟南芥组蛋白乙酰转移酶的特异性
  • 批准号:
    7355309
  • 财政年份:
    2006
  • 资助金额:
    $ 30.17万
  • 项目类别:
Role of RNA polymerase IV in the heterochromatic siRNA pathway
RNA聚合酶IV在异染色质siRNA途径中的作用
  • 批准号:
    7088118
  • 财政年份:
    2006
  • 资助金额:
    $ 30.17万
  • 项目类别:
Role of RNA polymerase IV in the heterochromatic siRNA pathway
RNA聚合酶IV在异染色质siRNA途径中的作用
  • 批准号:
    7220652
  • 财政年份:
    2006
  • 资助金额:
    $ 30.17万
  • 项目类别:
Roles of RNA Polymerases IV and V in siRNA-mediated gene silencing
RNA 聚合酶 IV 和 V 在 siRNA 介导的基因沉默中的作用
  • 批准号:
    9239452
  • 财政年份:
    2006
  • 资助金额:
    $ 30.17万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 30.17万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.17万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 30.17万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.17万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 30.17万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.17万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 30.17万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 30.17万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 30.17万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.17万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了